aluates Reports

$ 0.0

Automative

Global Innovative Biologics and Biosimilars Market Research Report 2025

Published Date: May 2025

Report Code: QYRE-Auto-1R14016

Global Innovative Biologics and Biosimilars Market Research Report 2023

BUY CHAPTERS

Global Innovative Biologics and Biosimilars Market Research Report 2025

Code: QYRE-Auto-1R14016

Report

May 2025

Pages:100

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Roche

Amgen Inc

AbbVie

Sanofi

Johnson & Johnson

Pfizer Inc

Novo Nordisk

Eli Lilly

Novartis

Merck

Biogen

Celltrion

SOBI

3SBio Inc

Changchun High Tech

Kanghong Pharma

Innovent Biologics

Gan & Lee

Tonghua Dongbao

United Laboratory

Innovative Biologics and Biosimilars Market Size

The global market for Innovative Biologics and Biosimilars was valued at US$ 441320 million in the year 2024 and is projected to reach a revised size of US$ 784010 million by 2031, growing at a CAGR of 8.7% during the forecast period.

Innovative Biologics and Biosimilars Market

Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Innovative Biologics and Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Innovative Biologics and Biosimilars.

The Innovative Biologics and Biosimilars market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Innovative Biologics and Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Innovative Biologics and Biosimilars companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Innovative Biologics and Biosimilars Market Report

Report Metric	Details
Report Name	Innovative Biologics and Biosimilars Market
Accounted market size in year	US$ 441320 million
Forecasted market size in 2031	US$ 784010 million
CAGR	8.7%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Monoclonal Antibodies Interferon Insulin Vaccines Others
Segment by Application	Hospital Retail Pharmacy Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, Biogen, Celltrion, Sobi, 3SBIO, Changchun High Tech, Kanghong Pharma, Innovent Biologics, Gan&Lee, Tonghua Dongbao, United Laboratory
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Innovative Biologics and Biosimilars company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Innovative Biologics and Biosimilars Market growing?

Ans: The Innovative Biologics and Biosimilars Market witnessing a CAGR of 8.7% during the forecast period 2025-2031.

What is the Innovative Biologics and Biosimilars Market size in 2031?

Ans: The Innovative Biologics and Biosimilars Market size in 2031 will be US$ 784010 million.

Who are the main players in the Innovative Biologics and Biosimilars Market report?

Ans: The main players in the Innovative Biologics and Biosimilars Market are Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, Biogen, Celltrion, Sobi, 3SBIO, Changchun High Tech, Kanghong Pharma, Innovent Biologics, Gan&Lee, Tonghua Dongbao, United Laboratory

What are the Application segmentation covered in the Innovative Biologics and Biosimilars Market report?

Ans: The Applications covered in the Innovative Biologics and Biosimilars Market report are Hospital, Retail Pharmacy, Other

What are the Type segmentation covered in the Innovative Biologics and Biosimilars Market report?

Ans: The Types covered in the Innovative Biologics and Biosimilars Market report are Monoclonal Antibodies, Interferon, Insulin, Vaccines, Others

Recommended Reports

Biologics & Biosimilars

Drug Delivery & Technologies

Diagnostics & Therapeutics

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Innovative Biologics and Biosimilars Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Monoclonal Antibodies

1.2.3 Interferon

1.2.4 Insulin

1.2.5 Vaccines

1.2.6 Others

1.3 Market by Application

1.3.1 Global Innovative Biologics and Biosimilars Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Retail Pharmacy

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Innovative Biologics and Biosimilars Market Perspective (2020-2031)

2.2 Global Innovative Biologics and Biosimilars Growth Trends by Region

2.2.1 Global Innovative Biologics and Biosimilars Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Innovative Biologics and Biosimilars Historic Market Size by Region (2020-2025)

2.2.3 Innovative Biologics and Biosimilars Forecasted Market Size by Region (2026-2031)

2.3 Innovative Biologics and Biosimilars Market Dynamics

2.3.1 Innovative Biologics and Biosimilars Industry Trends

2.3.2 Innovative Biologics and Biosimilars Market Drivers

2.3.3 Innovative Biologics and Biosimilars Market Challenges

2.3.4 Innovative Biologics and Biosimilars Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Innovative Biologics and Biosimilars Players by Revenue

3.1.1 Global Top Innovative Biologics and Biosimilars Players by Revenue (2020-2025)

3.1.2 Global Innovative Biologics and Biosimilars Revenue Market Share by Players (2020-2025)

3.2 Global Innovative Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Innovative Biologics and Biosimilars Revenue

3.4 Global Innovative Biologics and Biosimilars Market Concentration Ratio

3.4.1 Global Innovative Biologics and Biosimilars Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Innovative Biologics and Biosimilars Revenue in 2024

3.5 Global Key Players of Innovative Biologics and Biosimilars Head office and Area Served

3.6 Global Key Players of Innovative Biologics and Biosimilars, Product and Application

3.7 Global Key Players of Innovative Biologics and Biosimilars, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Innovative Biologics and Biosimilars Breakdown Data by Type

4.1 Global Innovative Biologics and Biosimilars Historic Market Size by Type (2020-2025)

4.2 Global Innovative Biologics and Biosimilars Forecasted Market Size by Type (2026-2031)

5 Innovative Biologics and Biosimilars Breakdown Data by Application

5.1 Global Innovative Biologics and Biosimilars Historic Market Size by Application (2020-2025)

5.2 Global Innovative Biologics and Biosimilars Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Innovative Biologics and Biosimilars Market Size (2020-2031)

6.2 North America Innovative Biologics and Biosimilars Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Innovative Biologics and Biosimilars Market Size by Country (2020-2025)

6.4 North America Innovative Biologics and Biosimilars Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Innovative Biologics and Biosimilars Market Size (2020-2031)

7.2 Europe Innovative Biologics and Biosimilars Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Innovative Biologics and Biosimilars Market Size by Country (2020-2025)

7.4 Europe Innovative Biologics and Biosimilars Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Innovative Biologics and Biosimilars Market Size (2020-2031)

8.2 Asia-Pacific Innovative Biologics and Biosimilars Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Innovative Biologics and Biosimilars Market Size by Region (2020-2025)

8.4 Asia-Pacific Innovative Biologics and Biosimilars Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Innovative Biologics and Biosimilars Market Size (2020-2031)

9.2 Latin America Innovative Biologics and Biosimilars Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Innovative Biologics and Biosimilars Market Size by Country (2020-2025)

9.4 Latin America Innovative Biologics and Biosimilars Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Innovative Biologics and Biosimilars Market Size (2020-2031)

10.2 Middle East & Africa Innovative Biologics and Biosimilars Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Innovative Biologics and Biosimilars Market Size by Country (2020-2025)

10.4 Middle East & Africa Innovative Biologics and Biosimilars Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Details

11.1.2 Roche Business Overview

11.1.3 Roche Innovative Biologics and Biosimilars Introduction

11.1.4 Roche Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.1.5 Roche Recent Development

11.2 Amgen

11.2.1 Amgen Company Details

11.2.2 Amgen Business Overview

11.2.3 Amgen Innovative Biologics and Biosimilars Introduction

11.2.4 Amgen Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.2.5 Amgen Recent Development

11.3 AbbVie

11.3.1 AbbVie Company Details

11.3.2 AbbVie Business Overview

11.3.3 AbbVie Innovative Biologics and Biosimilars Introduction

11.3.4 AbbVie Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.3.5 AbbVie Recent Development

11.4 Sanofi

11.4.1 Sanofi Company Details

11.4.2 Sanofi Business Overview

11.4.3 Sanofi Innovative Biologics and Biosimilars Introduction

11.4.4 Sanofi Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.4.5 Sanofi Recent Development

11.5 Johnson & Johnson

11.5.1 Johnson & Johnson Company Details

11.5.2 Johnson & Johnson Business Overview

11.5.3 Johnson & Johnson Innovative Biologics and Biosimilars Introduction

11.5.4 Johnson & Johnson Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.5.5 Johnson & Johnson Recent Development

11.6 Pfizer

11.6.1 Pfizer Company Details

11.6.2 Pfizer Business Overview

11.6.3 Pfizer Innovative Biologics and Biosimilars Introduction

11.6.4 Pfizer Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.6.5 Pfizer Recent Development

11.7 Novo Nordisk

11.7.1 Novo Nordisk Company Details

11.7.2 Novo Nordisk Business Overview

11.7.3 Novo Nordisk Innovative Biologics and Biosimilars Introduction

11.7.4 Novo Nordisk Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.7.5 Novo Nordisk Recent Development

11.8 Eli Lilly

11.8.1 Eli Lilly Company Details

11.8.2 Eli Lilly Business Overview

11.8.3 Eli Lilly Innovative Biologics and Biosimilars Introduction

11.8.4 Eli Lilly Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.8.5 Eli Lilly Recent Development

11.9 Novartis

11.9.1 Novartis Company Details

11.9.2 Novartis Business Overview

11.9.3 Novartis Innovative Biologics and Biosimilars Introduction

11.9.4 Novartis Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.9.5 Novartis Recent Development

11.10 Merck

11.10.1 Merck Company Details

11.10.2 Merck Business Overview

11.10.3 Merck Innovative Biologics and Biosimilars Introduction

11.10.4 Merck Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.10.5 Merck Recent Development

11.11 Biogen

11.11.1 Biogen Company Details

11.11.2 Biogen Business Overview

11.11.3 Biogen Innovative Biologics and Biosimilars Introduction

11.11.4 Biogen Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.11.5 Biogen Recent Development

11.12 Celltrion

11.12.1 Celltrion Company Details

11.12.2 Celltrion Business Overview

11.12.3 Celltrion Innovative Biologics and Biosimilars Introduction

11.12.4 Celltrion Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.12.5 Celltrion Recent Development

11.13 Sobi

11.13.1 Sobi Company Details

11.13.2 Sobi Business Overview

11.13.3 Sobi Innovative Biologics and Biosimilars Introduction

11.13.4 Sobi Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.13.5 Sobi Recent Development

11.14 3SBIO

11.14.1 3SBIO Company Details

11.14.2 3SBIO Business Overview

11.14.3 3SBIO Innovative Biologics and Biosimilars Introduction

11.14.4 3SBIO Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.14.5 3SBIO Recent Development

11.15 Changchun High Tech

11.15.1 Changchun High Tech Company Details

11.15.2 Changchun High Tech Business Overview

11.15.3 Changchun High Tech Innovative Biologics and Biosimilars Introduction

11.15.4 Changchun High Tech Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.15.5 Changchun High Tech Recent Development

11.16 Kanghong Pharma

11.16.1 Kanghong Pharma Company Details

11.16.2 Kanghong Pharma Business Overview

11.16.3 Kanghong Pharma Innovative Biologics and Biosimilars Introduction

11.16.4 Kanghong Pharma Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.16.5 Kanghong Pharma Recent Development

11.17 Innovent Biologics

11.17.1 Innovent Biologics Company Details

11.17.2 Innovent Biologics Business Overview

11.17.3 Innovent Biologics Innovative Biologics and Biosimilars Introduction

11.17.4 Innovent Biologics Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.17.5 Innovent Biologics Recent Development

11.18 Gan&Lee

11.18.1 Gan&Lee Company Details

11.18.2 Gan&Lee Business Overview

11.18.3 Gan&Lee Innovative Biologics and Biosimilars Introduction

11.18.4 Gan&Lee Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.18.5 Gan&Lee Recent Development

11.19 Tonghua Dongbao

11.19.1 Tonghua Dongbao Company Details

11.19.2 Tonghua Dongbao Business Overview

11.19.3 Tonghua Dongbao Innovative Biologics and Biosimilars Introduction

11.19.4 Tonghua Dongbao Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.19.5 Tonghua Dongbao Recent Development

11.20 United Laboratory

11.20.1 United Laboratory Company Details

11.20.2 United Laboratory Business Overview

11.20.3 United Laboratory Innovative Biologics and Biosimilars Introduction

11.20.4 United Laboratory Revenue in Innovative Biologics and Biosimilars Business (2020-2025)

11.20.5 United Laboratory Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Roche

Amgen Inc

AbbVie

Sanofi

Johnson & Johnson

Pfizer Inc

Novo Nordisk

Eli Lilly

Novartis

Merck

Biogen

Celltrion

SOBI

3SBio Inc

Changchun High Tech

Kanghong Pharma

Innovent Biologics

Gan & Lee

Tonghua Dongbao

United Laboratory

List of Tables

Table 1. Global Innovative Biologics and Biosimilars Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Monoclonal Antibodies

Table 3. Key Players of Interferon

Table 4. Key Players of Insulin

Table 5. Key Players of Vaccines

Table 6. Key Players of Others

Table 7. Global Innovative Biologics and Biosimilars Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Innovative Biologics and Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global Innovative Biologics and Biosimilars Market Size by Region (2020-2025) & (US$ Million)

Table 10. Global Innovative Biologics and Biosimilars Market Share by Region (2020-2025)

Table 11. Global Innovative Biologics and Biosimilars Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 12. Global Innovative Biologics and Biosimilars Market Share by Region (2026-2031)

Table 13. Innovative Biologics and Biosimilars Market Trends

Table 14. Innovative Biologics and Biosimilars Market Drivers

Table 15. Innovative Biologics and Biosimilars Market Challenges

Table 16. Innovative Biologics and Biosimilars Market Restraints

Table 17. Global Innovative Biologics and Biosimilars Revenue by Players (2020-2025) & (US$ Million)

Table 18. Global Innovative Biologics and Biosimilars Market Share by Players (2020-2025)

Table 19. Global Top Innovative Biologics and Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Innovative Biologics and Biosimilars as of 2024)

Table 20. Ranking of Global Top Innovative Biologics and Biosimilars Companies by Revenue (US$ Million) in 2024

Table 21. Global 5 Largest Players Market Share by Innovative Biologics and Biosimilars Revenue (CR5 and HHI) & (2020-2025)

Table 22. Global Key Players of Innovative Biologics and Biosimilars, Headquarters and Area Served

Table 23. Global Key Players of Innovative Biologics and Biosimilars, Product and Application

Table 24. Global Key Players of Innovative Biologics and Biosimilars, Date of Enter into This Industry

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Innovative Biologics and Biosimilars Market Size by Type (2020-2025) & (US$ Million)

Table 27. Global Innovative Biologics and Biosimilars Revenue Market Share by Type (2020-2025)

Table 28. Global Innovative Biologics and Biosimilars Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 29. Global Innovative Biologics and Biosimilars Revenue Market Share by Type (2026-2031)

Table 30. Global Innovative Biologics and Biosimilars Market Size by Application (2020-2025) & (US$ Million)

Table 31. Global Innovative Biologics and Biosimilars Revenue Market Share by Application (2020-2025)

Table 32. Global Innovative Biologics and Biosimilars Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 33. Global Innovative Biologics and Biosimilars Revenue Market Share by Application (2026-2031)

Table 34. North America Innovative Biologics and Biosimilars Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. North America Innovative Biologics and Biosimilars Market Size by Country (2020-2025) & (US$ Million)

Table 36. North America Innovative Biologics and Biosimilars Market Size by Country (2026-2031) & (US$ Million)

Table 37. Europe Innovative Biologics and Biosimilars Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 38. Europe Innovative Biologics and Biosimilars Market Size by Country (2020-2025) & (US$ Million)

Table 39. Europe Innovative Biologics and Biosimilars Market Size by Country (2026-2031) & (US$ Million)

Table 40. Asia-Pacific Innovative Biologics and Biosimilars Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 41. Asia-Pacific Innovative Biologics and Biosimilars Market Size by Region (2020-2025) & (US$ Million)

Table 42. Asia-Pacific Innovative Biologics and Biosimilars Market Size by Region (2026-2031) & (US$ Million)

Table 43. Latin America Innovative Biologics and Biosimilars Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Latin America Innovative Biologics and Biosimilars Market Size by Country (2020-2025) & (US$ Million)

Table 45. Latin America Innovative Biologics and Biosimilars Market Size by Country (2026-2031) & (US$ Million)

Table 46. Middle East & Africa Innovative Biologics and Biosimilars Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 47. Middle East & Africa Innovative Biologics and Biosimilars Market Size by Country (2020-2025) & (US$ Million)

Table 48. Middle East & Africa Innovative Biologics and Biosimilars Market Size by Country (2026-2031) & (US$ Million)

Table 49. Roche Company Details

Table 50. Roche Business Overview

Table 51. Roche Innovative Biologics and Biosimilars Product

Table 52. Roche Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 53. Roche Recent Development

Table 54. Amgen Company Details

Table 55. Amgen Business Overview

Table 56. Amgen Innovative Biologics and Biosimilars Product

Table 57. Amgen Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 58. Amgen Recent Development

Table 59. AbbVie Company Details

Table 60. AbbVie Business Overview

Table 61. AbbVie Innovative Biologics and Biosimilars Product

Table 62. AbbVie Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 63. AbbVie Recent Development

Table 64. Sanofi Company Details

Table 65. Sanofi Business Overview

Table 66. Sanofi Innovative Biologics and Biosimilars Product

Table 67. Sanofi Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 68. Sanofi Recent Development

Table 69. Johnson & Johnson Company Details

Table 70. Johnson & Johnson Business Overview

Table 71. Johnson & Johnson Innovative Biologics and Biosimilars Product

Table 72. Johnson & Johnson Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 73. Johnson & Johnson Recent Development

Table 74. Pfizer Company Details

Table 75. Pfizer Business Overview

Table 76. Pfizer Innovative Biologics and Biosimilars Product

Table 77. Pfizer Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 78. Pfizer Recent Development

Table 79. Novo Nordisk Company Details

Table 80. Novo Nordisk Business Overview

Table 81. Novo Nordisk Innovative Biologics and Biosimilars Product

Table 82. Novo Nordisk Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 83. Novo Nordisk Recent Development

Table 84. Eli Lilly Company Details

Table 85. Eli Lilly Business Overview

Table 86. Eli Lilly Innovative Biologics and Biosimilars Product

Table 87. Eli Lilly Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 88. Eli Lilly Recent Development

Table 89. Novartis Company Details

Table 90. Novartis Business Overview

Table 91. Novartis Innovative Biologics and Biosimilars Product

Table 92. Novartis Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 93. Novartis Recent Development

Table 94. Merck Company Details

Table 95. Merck Business Overview

Table 96. Merck Innovative Biologics and Biosimilars Product

Table 97. Merck Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 98. Merck Recent Development

Table 99. Biogen Company Details

Table 100. Biogen Business Overview

Table 101. Biogen Innovative Biologics and Biosimilars Product

Table 102. Biogen Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 103. Biogen Recent Development

Table 104. Celltrion Company Details

Table 105. Celltrion Business Overview

Table 106. Celltrion Innovative Biologics and Biosimilars Product

Table 107. Celltrion Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 108. Celltrion Recent Development

Table 109. Sobi Company Details

Table 110. Sobi Business Overview

Table 111. Sobi Innovative Biologics and Biosimilars Product

Table 112. Sobi Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 113. Sobi Recent Development

Table 114. 3SBIO Company Details

Table 115. 3SBIO Business Overview

Table 116. 3SBIO Innovative Biologics and Biosimilars Product

Table 117. 3SBIO Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 118. 3SBIO Recent Development

Table 119. Changchun High Tech Company Details

Table 120. Changchun High Tech Business Overview

Table 121. Changchun High Tech Innovative Biologics and Biosimilars Product

Table 122. Changchun High Tech Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 123. Changchun High Tech Recent Development

Table 124. Kanghong Pharma Company Details

Table 125. Kanghong Pharma Business Overview

Table 126. Kanghong Pharma Innovative Biologics and Biosimilars Product

Table 127. Kanghong Pharma Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 128. Kanghong Pharma Recent Development

Table 129. Innovent Biologics Company Details

Table 130. Innovent Biologics Business Overview

Table 131. Innovent Biologics Innovative Biologics and Biosimilars Product

Table 132. Innovent Biologics Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 133. Innovent Biologics Recent Development

Table 134. Gan&Lee Company Details

Table 135. Gan&Lee Business Overview

Table 136. Gan&Lee Innovative Biologics and Biosimilars Product

Table 137. Gan&Lee Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 138. Gan&Lee Recent Development

Table 139. Tonghua Dongbao Company Details

Table 140. Tonghua Dongbao Business Overview

Table 141. Tonghua Dongbao Innovative Biologics and Biosimilars Product

Table 142. Tonghua Dongbao Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 143. Tonghua Dongbao Recent Development

Table 144. United Laboratory Company Details

Table 145. United Laboratory Business Overview

Table 146. United Laboratory Innovative Biologics and Biosimilars Product

Table 147. United Laboratory Revenue in Innovative Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 148. United Laboratory Recent Development

Table 149. Research Programs/Design for This Report

Table 150. Key Data Information from Secondary Sources

Table 151. Key Data Information from Primary Sources

Table 152. Authors List of This Report

List of Figures

Figure 1. Innovative Biologics and Biosimilars Picture

Figure 2. Global Innovative Biologics and Biosimilars Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Innovative Biologics and Biosimilars Market Share by Type: 2024 VS 2031

Figure 4. Monoclonal Antibodies Features

Figure 5. Interferon Features

Figure 6. Insulin Features

Figure 7. Vaccines Features

Figure 8. Others Features

Figure 9. Global Innovative Biologics and Biosimilars Market Size by Application (2020-2031) & (US$ Million)

Figure 10. Global Innovative Biologics and Biosimilars Market Share by Application: 2024 VS 2031

Figure 11. Hospital Case Studies

Figure 12. Retail Pharmacy Case Studies

Figure 13. Other Case Studies

Figure 14. Innovative Biologics and Biosimilars Report Years Considered

Figure 15. Global Innovative Biologics and Biosimilars Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 16. Global Innovative Biologics and Biosimilars Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global Innovative Biologics and Biosimilars Market Share by Region: 2024 VS 2031

Figure 18. Global Innovative Biologics and Biosimilars Market Share by Players in 2024

Figure 19. Global Top Innovative Biologics and Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Innovative Biologics and Biosimilars as of 2024)

Figure 20. The Top 10 and 5 Players Market Share by Innovative Biologics and Biosimilars Revenue in 2024

Figure 21. North America Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. North America Innovative Biologics and Biosimilars Market Share by Country (2020-2031)

Figure 23. United States Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Canada Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe Innovative Biologics and Biosimilars Market Share by Country (2020-2031)

Figure 27. Germany Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. France Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. U.K. Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Italy Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Russia Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Nordic Countries Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific Innovative Biologics and Biosimilars Market Share by Region (2020-2031)

Figure 35. China Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Japan Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. South Korea Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Southeast Asia Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. India Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Australia Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America Innovative Biologics and Biosimilars Market Share by Country (2020-2031)

Figure 43. Mexico Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Brazil Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa Innovative Biologics and Biosimilars Market Share by Country (2020-2031)

Figure 47. Turkey Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Saudi Arabia Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. UAE Innovative Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Roche Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 51. Amgen Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 52. AbbVie Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 53. Sanofi Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 54. Johnson & Johnson Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 55. Pfizer Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 56. Novo Nordisk Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 57. Eli Lilly Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 58. Novartis Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 59. Merck Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 60. Biogen Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 61. Celltrion Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 62. Sobi Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 63. 3SBIO Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 64. Changchun High Tech Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 65. Kanghong Pharma Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 66. Innovent Biologics Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 67. Gan&Lee Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 68. Tonghua Dongbao Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 69. United Laboratory Revenue Growth Rate in Innovative Biologics and Biosimilars Business (2020-2025)

Figure 70. Bottom-up and Top-down Approaches for This Report

Figure 71. Data Triangulation

Figure 72. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Innovations in Biologics and Biosimilars Market Research Report 2024

Global Biologics and Biosimilars Market Research Report 2025

Biotech Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Generic vs Innovator Drugs Market Research Report 2024

Global Biologic Medical Product Market Research Report 2025

Biologics Drug Discovery and Development Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Monoclonal antibodies mAbs Biosimilars Market Research Report 2024

Veterinary Biologics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Biotechnological Drugs Market Research Report 2025

Global Biologics Drug Development Market Research Report 2024

Global Biotechnology Contract Manufacturing Market Research Report 2024

Global Subcutaneous Biologics Market Research Report 2024

Insulin Biologics and Biosimilars Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Cell Line Development for Biologics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Chemical Drug and Biologic Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Biosimilar of Remicade Market

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-14Y6812

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-34O3983

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9V17601

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22C17047

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions